Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.24
INCY's Cash-to-Debt is ranked lower than
77% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. INCY: 1.24 )
Ranked among companies with meaningful Cash-to-Debt only.
INCY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.5  Med: 1.19 Max: No Debt
Current: 1.24
Equity-to-Asset 0.26
INCY's Equity-to-Asset is ranked lower than
83% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. INCY: 0.26 )
Ranked among companies with meaningful Equity-to-Asset only.
INCY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.95  Med: 0.05 Max: 0.78
Current: 0.26
-0.95
0.78
Interest Coverage 3.74
INCY's Interest Coverage is ranked lower than
92% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INCY: 3.74 )
Ranked among companies with meaningful Interest Coverage only.
INCY' s Interest Coverage Range Over the Past 10 Years
Min: 0.02  Med: 0.72 Max: 3.74
Current: 3.74
0.02
3.74
Piotroski F-Score: 6
Altman Z-Score: 14.07
Beneish M-Score: -1.51
WACC vs ROIC
14.73%
70.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 13.11
INCY's Operating Margin % is ranked higher than
82% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. INCY: 13.11 )
Ranked among companies with meaningful Operating Margin % only.
INCY' s Operating Margin % Range Over the Past 10 Years
Min: -4064.53  Med: -2.74 Max: 13.11
Current: 13.11
-4064.53
13.11
Net Margin % 9.43
INCY's Net Margin % is ranked higher than
81% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. INCY: 9.43 )
Ranked among companies with meaningful Net Margin % only.
INCY' s Net Margin % Range Over the Past 10 Years
Min: -4565.45  Med: -21.09 Max: 9.43
Current: 9.43
-4565.45
9.43
ROE % 35.08
INCY's ROE % is ranked higher than
96% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. INCY: 35.08 )
Ranked among companies with meaningful ROE % only.
INCY' s ROE % Range Over the Past 10 Years
Min: 14.59  Med: 24.94 Max: 35.29
Current: 35.08
14.59
35.29
ROA % 7.76
INCY's ROA % is ranked higher than
89% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. INCY: 7.76 )
Ranked among companies with meaningful ROA % only.
INCY' s ROA % Range Over the Past 10 Years
Min: -70.43  Med: -15.38 Max: 7.88
Current: 7.76
-70.43
7.88
ROC (Joel Greenblatt) % 114.76
INCY's ROC (Joel Greenblatt) % is ranked higher than
95% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. INCY: 114.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INCY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4727.38  Med: -134.72 Max: 115.22
Current: 114.76
-4727.38
115.22
3-Year Revenue Growth Rate 33.50
INCY's 3-Year Revenue Growth Rate is ranked higher than
80% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. INCY: 33.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INCY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.4  Med: 19.6 Max: 194.1
Current: 33.5
-61.4
194.1
GuruFocus has detected 4 Warning Signs with Incyte Corp $INCY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INCY's 10-Y Financials

Financials (Next Earnings Date: 2017-05-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

INCY Guru Trades in Q1 2016

Jim Simons 304,000 sh (New)
Joel Greenblatt 52,500 sh (New)
Paul Tudor Jones 77,400 sh (+809.20%)
Vanguard Health Care Fund 16,227,748 sh (+68.76%)
Ken Fisher 14,839 sh (+0.14%)
George Soros Sold Out
Frank Sands 3,819,401 sh (-13.61%)
Eaton Vance Worldwide Health Sciences Fund 429,400 sh (-0.49%)
» More
Q2 2016

INCY Guru Trades in Q2 2016

George Soros 7,500 sh (New)
Joel Greenblatt 142,607 sh (+171.63%)
Frank Sands 4,467,286 sh (+16.96%)
Paul Tudor Jones 81,409 sh (+5.18%)
Vanguard Health Care Fund 16,227,748 sh (unchged)
Ken Fisher 14,818 sh (-0.14%)
Jim Simons 164,567 sh (-45.87%)
Eaton Vance Worldwide Health Sciences Fund 363,900 sh (-15.25%)
» More
Q3 2016

INCY Guru Trades in Q3 2016

John Burbank 243,396 sh (New)
Steven Cohen 68,000 sh (New)
Jana Partners 58,385 sh (New)
Pioneer Investments 80,822 sh (New)
Andreas Halvorsen 503,645 sh (New)
Ken Fisher 14,917 sh (+0.67%)
Vanguard Health Care Fund 16,227,748 sh (unchged)
Frank Sands 4,124,074 sh (-7.68%)
Joel Greenblatt 108,099 sh (-24.20%)
George Soros 5,200 sh (-30.67%)
Jim Simons 62,900 sh (-61.78%)
Paul Tudor Jones 10,933 sh (-86.57%)
Eaton Vance Worldwide Health Sciences Fund 237,999 sh (-34.60%)
» More
Q4 2016

INCY Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 91,970 sh (New)
Pioneer Investments 623,117 sh (+670.97%)
Steven Cohen 438,801 sh (+545.30%)
Jana Partners 86,616 sh (+48.35%)
Andreas Halvorsen 730,452 sh (+45.03%)
Ken Fisher 14,917 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Frank Sands 3,652,652 sh (-11.43%)
Vanguard Health Care Fund 11,635,908 sh (-28.30%)
Joel Greenblatt 59,202 sh (-45.23%)
Paul Tudor Jones 4,203 sh (-61.56%)
John Burbank 63,593 sh (-73.87%)
Eaton Vance Worldwide Health Sciences Fund 228,436 sh (-4.02%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:OTCPK:ALIOY, NAS:ALXN, NAS:VRTX, NAS:REGN, NAS:BMRN, OTCPK:UCBJF, OTCPK:CSLLY, NAS:MDVN, NAS:GRFS, OTCPK:GMXAY, OTCPK:NVZMY, NAS:SGEN, NAS:ALKS, NAS:TSRO, NAS:JAZZ, NAS:UTHR, NAS:EXEL, NAS:BIVV, NAS:IONS, NAS:ARIA » details
Traded in other countries:ICY.Germany,
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug is Jakafi, a myelofibrosis treatment, which has been partnered with Novartis. Incyte's pipeline includes a rheumatoid arthritis treatment that has been licensed by Eli Lilly and a broad array of oncology and autoimmune programs.

Top Ranked Articles about Incyte Corp

Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences Viking Global adds to biotech holdings with 7.8% of shares
Andreas Halvorsen (Trades, Portfolio)’s $30 billion Viking Global hedge fund has invested in a new class of cancer drugs being developed by Calithera Biosciences Inc. (NASDAQ:CALA), it announced on Tuesday evening, via a stake worth 7.8% of its shares. Read more...
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions Solid growth has attended the sector until this year
Against a backdrop of solid growth for the sector, the outperforming Vanguard Health Care Fund (Trades, Portfolio) replenished its portfolio in the first quarter with increases in 27 holdings and reductions or removal of 28 holdings. Read more...
Vanguard Boosts Stake in Incyte in 1st Quarter Guru sells holdings in CVS Health, Edwards Lifesciences, Monsanto
Vanguard Health Care Fund continued a streak of double-digit returns in 2015 with returns of 12.65%. That is below the fund’s returns levels of 2014 (28.52%) and 2013 (43.19%), but it is still in double digits, which was a considerable achievement in 2015’s challenging investing environment. Read more...

Ratios

vs
industry
vs
history
PE Ratio 262.80
INCY's PE Ratio is ranked lower than
96% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. INCY: 262.80 )
Ranked among companies with meaningful PE Ratio only.
INCY' s PE Ratio Range Over the Past 10 Years
Min: 100.16  Med: 261.88 Max: 5661.5
Current: 262.8
100.16
5661.5
Forward PE Ratio 156.25
INCY's Forward PE Ratio is ranked lower than
93% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 20.12 vs. INCY: 156.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 262.80
INCY's PE Ratio without NRI is ranked lower than
95% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 28.10 vs. INCY: 262.80 )
Ranked among companies with meaningful PE Ratio without NRI only.
INCY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 100.16  Med: 261.88 Max: 5661.5
Current: 262.8
100.16
5661.5
Price-to-Owner-Earnings 172.65
INCY's Price-to-Owner-Earnings is ranked lower than
88% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 31.38 vs. INCY: 172.65 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
INCY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.73  Med: 125.56 Max: 3235.14
Current: 172.65
10.73
3235.14
PB Ratio 62.70
INCY's PB Ratio is ranked lower than
99% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. INCY: 62.70 )
Ranked among companies with meaningful PB Ratio only.
INCY' s PB Ratio Range Over the Past 10 Years
Min: 40.27  Med: 66.91 Max: 391.93
Current: 62.7
40.27
391.93
PS Ratio 24.39
INCY's PS Ratio is ranked lower than
63% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. INCY: 24.39 )
Ranked among companies with meaningful PS Ratio only.
INCY' s PS Ratio Range Over the Past 10 Years
Min: 7.13  Med: 21.29 Max: 239.71
Current: 24.39
7.13
239.71
Price-to-Free-Cash-Flow 146.46
INCY's Price-to-Free-Cash-Flow is ranked lower than
95% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 24.12 vs. INCY: 146.46 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
INCY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.56  Med: 142.21 Max: 1176.61
Current: 146.46
6.56
1176.61
Price-to-Operating-Cash-Flow 88.55
INCY's Price-to-Operating-Cash-Flow is ranked lower than
87% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 20.83 vs. INCY: 88.55 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INCY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.52  Med: 84.52 Max: 775.18
Current: 88.55
6.52
775.18
EV-to-EBIT 193.19
INCY's EV-to-EBIT is ranked lower than
99% of the 320 Companies
in the Global Biotechnology industry.

( Industry Median: 21.73 vs. INCY: 193.19 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8436.1  Med: -8.35 Max: 1546.6
Current: 193.19
-8436.1
1546.6
EV-to-EBITDA 138.02
INCY's EV-to-EBITDA is ranked lower than
93% of the 355 Companies
in the Global Biotechnology industry.

( Industry Median: 16.79 vs. INCY: 138.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
INCY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -662.5  Med: -6.25 Max: 2618.5
Current: 138.02
-662.5
2618.5
Current Ratio 3.64
INCY's Current Ratio is ranked lower than
54% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. INCY: 3.64 )
Ranked among companies with meaningful Current Ratio only.
INCY' s Current Ratio Range Over the Past 10 Years
Min: 2.13  Med: 4.98 Max: 15.29
Current: 3.64
2.13
15.29
Quick Ratio 3.62
INCY's Quick Ratio is ranked lower than
51% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. INCY: 3.62 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s Quick Ratio Range Over the Past 10 Years
Min: 2.13  Med: 4.97 Max: 15.29
Current: 3.62
2.13
15.29
Days Inventory 21.83
INCY's Days Inventory is ranked higher than
87% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. INCY: 21.83 )
Ranked among companies with meaningful Days Inventory only.
INCY' s Days Inventory Range Over the Past 10 Years
Min: 14.49  Med: 46.41 Max: 323.15
Current: 21.83
14.49
323.15
Days Sales Outstanding 49.11
INCY's Days Sales Outstanding is ranked higher than
59% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. INCY: 49.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.25  Med: 45.23 Max: 6447.52
Current: 49.11
12.25
6447.52
Days Payable 474.22
INCY's Days Payable is ranked higher than
93% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. INCY: 474.22 )
Ranked among companies with meaningful Days Payable only.
INCY' s Days Payable Range Over the Past 10 Years
Min: 407.13  Med: 2972.25 Max: 32457.1
Current: 474.22
407.13
32457.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
INCY's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. INCY: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INCY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.4  Med: -7.5 Max: -0.6
Current: -5
-13.4
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 90.45
INCY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
95% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 3.58 vs. INCY: 90.45 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
INCY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 51.83  Med: 58.47 Max: 90.94
Current: 90.45
51.83
90.94
Price-to-Median-PS-Value 1.15
INCY's Price-to-Median-PS-Value is ranked lower than
59% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. INCY: 1.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INCY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.83 Max: 4.65
Current: 1.15
0.15
4.65
Earnings Yield (Greenblatt) % 0.52
INCY's Earnings Yield (Greenblatt) % is ranked higher than
75% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. INCY: 0.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INCY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 0.6 Max: 1.3
Current: 0.52
0.1
1.3

More Statistics

Revenue (TTM) (Mil) $1,106
EPS (TTM) $ 0.53
Beta1.67
Short Percentage of Float8.08%
52-Week Range $67.52 - 153.15
Shares Outstanding (Mil)203.82

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,554 1,654 1,926
EPS ($) 0.85 1.10 1.00
EPS without NRI ($) 0.85 1.10 1.00
EPS Growth Rate
(Future 3Y To 5Y Estimate)
169.29%
Dividends per Share ($)
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences Feb 22 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Jan 24 2017 
Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Frank Sands Acquires Stake in Netflix Feb 23 2016 
Top Insider Trades of the Past Week Feb 19 2016 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 

More From Other Websites
Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs Mar 17 2017
Incyte (INCY) Up 26.2% Since Earnings Report: Can It Continue? Mar 17 2017
Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals Mar 16 2017
Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data Mar 16 2017
After Soaring to $150, Can Incyte Stir Up More Upside? Mar 15 2017
Wait, Gilead Might Actually Hit Its 1st Quarter Numbers?!?! Mar 15 2017
Gilead Looking To Buy Incyte? It Makes Sense Mar 14 2017
Incyte Spikes To Record High On Rumors Gilead Could Acquire It Mar 13 2017
Is Incyte For Sale? Mar 13 2017
Gilead Sciences: Is an Incyte Deal 'Reasonable'? Mar 13 2017
Incyte Corporation Stock Rises on Price Target Increase Mar 13 2017
The Hot Stock: Incyte Soars 8.1% on Gilead Takeover Speculation Mar 10 2017
Incyte Pops on Continued Gilead Takeout Speculation Mar 10 2017
INCYTE CORP Files SEC form 8-K/A, Financial Statements and Exhibits Mar 10 2017
Dear Gilead: Buy Something — Anything — Analyst Pleads Mar 10 2017
Analyst Pleads With Gilead To Buy — And It May Have Worked Mar 10 2017
How Gilead Is Paying The Price For Actually Curing A Disease Mar 10 2017
Incyte Likely to Incite Further Gains Mar 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)